AbbVie Inc.
(ABBV)CIK 1551152 · SEC filings only
Not gradedDividend record
shown as history
shown as history
company entity
55 dividend record entries
Dividend record — shown as history, not graded
A declared dividend is a reported fact, not a promise we grade. Here's the record — raises, holds, and cuts — each linked to its source filing.
Dividend record
55 declarations · 15 raised · 37 held · 0 cut · held 52 quarters
- HELD$1.7300/shperiod ended 2026-06-30Filing ↗
- HELD$1.7300/shperiod ended 2026-03-31Filing ↗
- RAISED$1.7300/shperiod ended 2025-12-31Filing ↗
- HELD$1.6400/shperiod ended 2025-09-30Filing ↗
- HELD$1.6400/shperiod ended 2025-06-30Filing ↗
- HELD$1.6400/shperiod ended 2025-03-31Filing ↗
- RAISED$1.6400/shperiod ended 2024-12-31Filing ↗
- HELD$1.5500/shperiod ended 2024-09-30Filing ↗
- HELD$1.5500/shperiod ended 2024-06-30Filing ↗
- HELD$1.5500/shperiod ended 2024-03-31Filing ↗
- RAISED$1.5500/shperiod ended 2023-12-31Filing ↗
- HELD$1.4800/shperiod ended 2023-09-08Filing ↗
Not yet gradedBuyback record
harness minimum not met
harness minimum not met
company entity
2 resolved promises
Not enough resolved promises to grade
2 of the 4 resolved buyback promises needed to publish a reliability grade. Here's what we're tracking — we never show a grade we can't back with receipts.
Resolved promises
Pro
Full say-do history
Free scorecards show the 12 most recent resolved buyback promises. See the complete multi-year record with Pro.
See Pro →Credibility timeline
20152017
Timeline as a list
- Aug 7, 2015PARTIALAbbVie’s board authorized a share repurchase program of up to $1.5 billion of the company’s outstanding common stock
- Feb 17, 2017PARTIALthe AbbVie board of directors authorized a new $5 billion stock repurchase program
FGuidance record
grade
grade
company entity
8 resolved promises
Sector median (Life Sciences): B across 7 graded companies
Resolved promises
Pro
Full say-do history
Free scorecards show the 12 most recent resolved guidance promises. See the complete multi-year record with Pro.
See Pro →Guidance by basis
24 of 32 guidance figures that were graded or dropped for basis could not be graded on the same basis (75%). Guidance marked “not judged” is in neither number.
| Guidance type | Said | Graded | Dropped | Other |
|---|---|---|---|---|
| Revenue · basis not stated | 1 | 1 | 0 | 0 |
| EPS · GAAP | 13 | 7 | 0 | 6 |
| EPS · non-GAAPcannot be graded | 49 | 0 | 24 | 25 |
Said counts every revenue and EPS guidance figure on record. Dropped counts figures whose period was reported but which have no comparable GAAP actual in SEC XBRL. Other covers open, superseded, withdrawn and otherwise unresolved figures. The coverage note below counts every figure shown but not graded, including figures whose period has not been reported, so it can be larger.
Guidance shown, not graded (49)
We show what was said — with its source filing — but never score it. The line under each statement says why.
- eps guidance q · Oct 5, 2026$ 3.73 $ 3.77Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Oct 5, 2026$ 13.76 $ 13.96Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Jul 6, 2026$ 13.91 $ 14.11Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance q · Jul 6, 2026$ 3.57 $ 3.61Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance q · Apr 3, 2026$ 2.56 $ 2.60Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Apr 3, 2026$ 13.96 $ 14.16Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance q · Jan 7, 2026$ 2.61 $ 2.65Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Jan 7, 2026$ 9.90 $ 9.94Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Oct 3, 2025$ 10.38 $ 10.58Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance q · Oct 3, 2025$ 1.74 $ 1.78Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance q · Jul 3, 2025$ 2.84 $ 2.88Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Jul 3, 2025$ 11.67 $ 11.87Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance q · Apr 3, 2025$ 2.34 $ 2.38Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Apr 3, 2025$ 11.99 $ 12.19Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance q · Jan 6, 2025$ 2.06 $ 2.10Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Jan 6, 2025$ 10.02 $ 10.06Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance q · Oct 3, 2024$ 2.88 $ 2.92Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Oct 3, 2024$ 10.67 $ 10.87Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Jul 3, 2024$ 10.61 $ 10.81Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance q · Jul 3, 2024$ 2.53 $ 2.57Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance q · Apr 3, 2024$ 2.18 $ 2.22Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Apr 3, 2024$ 10.97 $ 11.17Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance q · Jan 5, 2024$ 2.72 $ 2.76Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Jan 5, 2024$ 11.04 $ 11.08Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Oct 4, 2023$ 10.86 $ 11.06Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance q · Oct 4, 2023$ 2.76 $ 2.86Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance q · Jul 6, 2023$ 2.75 $ 2.85Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Jul 6, 2023$ 10.57 $ 10.97Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance q · Apr 5, 2023$ 2.31 $ 2.41Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Apr 5, 2023$ 10.62 $ 11.02Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance q · Jan 6, 2023$ 3.51 $ 3.55Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Jan 6, 2023$ 13.70 $ 13.74Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance q · Oct 5, 2022$ 3.53 $ 3.57Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Oct 5, 2022$ 13.76 $ 13.96Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance q · Jul 6, 2022$ 3.24 $ 3.28Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Jul 6, 2022$ 13.78 $ 13.98Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Oct 30, 2020Updates 2020 Adjusted Diluted EPS Guidance Range from $10.35 to $10.45 to $10.47 to $10.49Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Jan 27, 2017AbbVie expects to deliver adjusted diluted EPS guidance for the full-year 2017 of $5.44 to $5.54Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Oct 28, 2016AbbVie is raising its adjusted diluted EPS guidance for the full-year 2016 to $4.80 to $4.82Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Apr 28, 2016AbbVie now expects diluted earnings-per-share of $4.62 to $4.82 on an adjusted basis for the full-year 2016Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Jan 29, 2016Confirms 2016 Adjusted EPS Guidance Range of $4.90 to $5.10Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Jul 24, 2015AbbVie is confirming its adjusted diluted earnings-per-share guidance for the full-year 2015 of $4.10 to $4.30Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Apr 23, 2015Today, AbbVie is raising its adjusted diluted earnings-per-share guidance for the full-year 2015 to $4.10 to $4.30Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Oct 31, 2014Significantly Raises 2014 Adjusted EPS Guidance Range to $3.25 to $3.27Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance q · Jul 25, 2014AbbVie is issuing diluted earnings-per-share guidance for the third-quarter 2014 of $0.77 to $0.79 on an adjusted basisUnverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Jul 25, 2014AbbVie is confirming its recently-increased diluted earnings-per-share guidance for the full-year 2014 of $3.06 to $3.16 on an adjusted basisUnverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Jan 31, 2014AbbVie is issuing diluted earnings-per-share guidance for the full-year 2014 of $3.00 to $3.10 on an adjusted basisUnverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Oct 25, 2013AbbVie is raising its diluted earnings-per-share guidance for the full-year 2013 to $3.11 to $3.13Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
- eps guidance fy · Apr 26, 2013or $3.03 to $3.13 on an adjusted basisUnverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
Open promises (0) · 6 superseded
Superseded · eps guidance fy
AbbVie is confirming its diluted earnings-per-share guidance for the full-year 2013 of $2.66 to $2.76 on a GAAP basis
revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy
AbbVie’s diluted earnings-per-share guidance is $3.57 to $3.77 on a GAAP basis
revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy
Including these items, AbbVie’s diluted earnings-per-share guidance is $3.87 to $4.07 on a GAAP basis
revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy
or $2.69 to $2.79 on a GAAP basis
revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy
or $2.63 to $2.73 on a GAAP basis
revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy
AbbVie’s diluted earnings-per-share guidance is $4.45 to $4.65 on a GAAP basis
revised by a later guidancereceipt (opens in a new tab)
Credibility timeline
20142021
Timeline as a list
- Feb 21, 2014IN LINEor $2.54 to $2.56 on a GAAP basis
- Nov 7, 2014BELOWor $0.68 to $0.70 on a GAAP basis
- Feb 20, 2015BELOWGAAP EPS Guidance Range is $1.15 to $1.17
- Feb 20, 2015ABOVEAbbVie expects 2014 revenue of approximately $19 billion
- Feb 19, 2016BELOWAbbVie’s diluted earnings-per-share guidance is $3.26 to $3.46 on a GAAP basis
- Feb 17, 2017BELOWAbbVie is raising GAAP diluted EPS guidance for the full-year 2016 to $3.74 to $3.76
- Feb 16, 2018BELOWAbbVie is issuing GAAP diluted EPS guidance for the full-year 2017 of $4.55 to $4.65
- Feb 19, 2021BELOWUpdates 2020 GAAP Diluted EPS Guidance Range from $4.12 to $4.22 to $3.89 to $3.91